Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

117.00EUR
22 Jan 2020
Change (% chg)

-- (--)
Prev Close
€117.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
503,080
52-wk High
€117.95
52-wk Low
€85.84

Latest Key Developments (Source: Significant Developments)

Merck: EUR 13 Mln Seed Fund Targeted At Startups In China
Friday, 18 Oct 2019 

Oct 18 (Reuters) - MERCK KGAA ::ANNOUNCED AN RMB 100 MILLION (€ 13 MILLION) SEED FUND TARGETED AT STARTUPS IN CHINA.  Full Article

Progyny Says Merck Ventures Owns 6.6% Stake In Co Prior To IPO
Saturday, 28 Sep 2019 

Sept 27 (Reuters) - Progyny::PROGYNY SAYS MERCK VENTURES OWNS 6.6% STAKE IN CO PRIOR TO THE IPO.PROGYNY SAYS TPG BIOTECHNOLOGY PARTNERS III, L.P. OWNS 27.7% STAKE IN CO PRIOR TO THE IPO.  Full Article

Merck KGaA Wins CHMP Positive Opinion For Rebif Label Amendment
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Merck KGaA ::CHMP POSITIVE OPINION FOR REBIF® LABEL AMENDMENT DURING PREGNANCY AS CLINICALLY NEEDED AND WHILE BREASTFEEDING.COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) OPINION MAKES INTERFERON BETA, INCLUDING REBIF, A TREATMENT OPTION FOR RELAPSING MULTIPLE SCLEROSIS THAT MAY BE CONTINUED INTO PREGNANCY IF CLINICALLY NEEDED AND WHILE BREASTFEEDING.  Full Article

Merck KGaA: Positive EU Opinion On Avelumab For Renal Cell Cancer
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Merck KGaA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) ADOPTED A POSITIVE OPINION RECOMMENDING APPROVAL OF BAVENCIO® (AVELUMAB) IN COMBINATION WITH AXITINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).OPINION WAS BASED ON POSITIVE FINDINGS FROM THE PHASE III JAVELIN RENAL 101 STUDY.  Full Article

Y-Trap Enters Collaboration With Merck KGaA, Darmstadt, Germany, To Develop Novel Antibody-Ligand Traps For Immuno-Oncology
Thursday, 19 Sep 2019 

Sept 19 (Reuters) - Merck KGaA ::Y-TRAP ENTERS COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, TO DEVELOP NOVEL ANTIBODY-LIGAND TRAPS FOR IMMUNO-ONCOLOGY.Y-TRAP - UNDER AGREEMENT, MERCK KGAA, DARMSTADT, GERMANY, WILL PROVIDE Y-TRAP WITH AN UPFRONT PAYMENT IN ADDITION TO MILESTONE PAYMENTS AND ROYALTIES.Y-TRAP INC - SIGNED AGREEMENT WITH MERCK KGAA FOR EXCLUSIVE DEVELOPMENT OF MULTIPLE SPECIFIC ANTIBODY-LIGAND TRAPS FOR CANCER IMMUNOTHERAPY.  Full Article

Merck KGaA Confirms 2019 Targets
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Merck KGaA ::PERFORMANCE MATERIALS IS ON TRACK WITH ITS TRANSFORMATION PROGRAM AND EXPECTS TO RESUME ORGANIC GROWTH AS OF 2020.FOCUS ON RAPID DELEVERAGING AND STRINGENT COST DISCIPLINE.EXPECTS TO ACHIEVE SUSTAINABLE PROFITABLE GROWTH IN ALL THREE BUSINESS SECTORS IN THE COMING YEARS.FOR 2019, WE CONTINUE TO ASSUME THAT THE GROUP WILL INCREASE ALL ITS KEY FIGURES: SALES, EBITDA PRE AND EPS PRE.HAVE OUR SIGHTS FIRMLY SET ON PROFITABLE GROWTH FOR 2020 AND BEYOND.WILL FOCUS ON GENERATING CASH IN ORDER TO QUICKLY LOWER ITS POST-ACQUISITION DEBT.BY 2022, COMPANY AIMS TO ACHIEVE ADDITIONAL ANNUAL SALES OF AROUND € 2 BILLION WITH NEW MEDICINES AND IS IN LINE WITH PLAN.CORE BUSINESS WITH EXISTING MEDICINES BASIS FOR SUSTAINABLE GROWTH OF HEALTHCARE BUSINESS SECTOR, AIMING FOR SALES TO AT LEAST REMAIN STABLE.IN COMING YEARS, LIFE SCIENCE BUSINESS SECTOR PLANS TO DELIVER ANNUAL GROWTH OF 5% TO 8% PER YEAR.PERFORMANCE MATERIALS EXPECTED TO RESUME GROWTH AS OF 2020.AS OF 2020, MERCK ASSUMES THAT AVERAGE ANNUAL SALES GROWTH IN PERFORMANCE MATERIALS WILL RANGE BETWEEN 2% AND 3%.PERFORMANCE MATERIALS LONG-TERM EBITDA PRE MARGIN TARGET IS AROUND 30%.OLED MATERIALS BUSINESS IS SHOWING TREMENDOUS GROWTH DYNAMIC.  Full Article

GSK Announces Jack Bailey, President U.S. Pharmaceuticals, Decided To Step Down
Monday, 12 Aug 2019 

Aug 12 (Reuters) - GlaxoSmithKline PLC ::JACK BAILEY, PRESIDENT U.S. PHARMACEUTICALS HAS DECIDED TO STEP DOWN FROM ROLE AT END OF YEAR.BAILEY TO BE SUCCEEDED BY MAYA MARTINEZ-DAVIS.MARTINEZ-DAVIS TO JOIN GSK IN MID-SEPT AND WILL ASSUME RESPONSIBILITY OF THE U.S. PHARMACEUTICALS BUSINESS ON JAN 1, 2020.  Full Article

Merck Buys BSSN Software
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - MERCK KGAA ::ACQUIRES BSSN SOFTWARE.FINANCIAL DETAILS WERE NOT DISCLOSED.BSSN’S EMPLOYEES HAVE JOINED MERCK AS PART OF ITS APPLIED DIGITAL LAB PRODUCTIVITY SOLUTIONS TEAM.  Full Article

Intermolecular Stockholders Approve Merck KGaA, Darmstadt, Germany's Proposed Acquisition Of Intermolecular
Thursday, 18 Jul 2019 

July 17 (Reuters) - Intermolecular Inc ::INTERMOLECULAR STOCKHOLDERS APPROVE MERCK KGAA, DARMSTADT, GERMANY'S PROPOSED ACQUISITION OF INTERMOLECULAR.INTERMOLECULAR INC - MERCK KGAA'S PROPOSED ACQUISITION OF INTERMOLECULAR IS EXPECTED TO CLOSE IN SECOND HALF OF 2019.INTERMOLECULAR - HOLDERS OF ABOUT 72% OF INTERMOLECULAR'S OUTSTANDING COMMON STOCK VOTED IN FAVOR OF PROPOSED MERGER TRANSACTION WITH MERCK KGAA.  Full Article

Merck KGaA Says Has Placed 2 Billion EUR Worth Of Bonds To Fund Acquisition Of Versum Materials Inc.
Monday, 1 Jul 2019 

Merck Kgaa ::SAYS HAS PLACED 2 BILLION EUR WORTH OF BONDS TO FUND ACQUISITION OF VERSUM MATERIALS INC..  Full Article

German stocks - Factors to watch on November 20

BERLIN/FRANKFURT, Nov 20 The following are some of the factors that may move German stocks on Wednesday: